An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins
Journal of Cachexia, Sarcopenia and Muscle · 2025
DOI: 10.1002/jcsm.70116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2025. Verfasst von Louise Medaer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Disease Modelling, Targeted Drug Discovery and Gene Therapy (ADVANTAGE), Department of Pharmacological and Pharmaceutical Sciences, Faculty …. Hauptthemen laut MEDLINE: Cystinosis, Myoblasts, Muscular Diseases, Muscle Development. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation Flanders (FWO), Cystinosis Ireland, Cystinosis Foundation UK.
Abstract (Originalsprache)
Background
Cystinosis is a rare multisystem, autosomal recessive disease caused by dysfunction or loss of cystinosin (CTNS), which results in lysosomal cystine accumulation, primarily affecting the kidneys. Advances in renal transplantation, cysteamine treatment and improved medical care have increased life expectancy, revealing additional systemic phenotypes like myopathy later in life. Muscle weakness is a major concern leading to life‐threatening events in patients, and yet the aetiology of cystinosis myopathy remains to be elucidated.
Methods
We generated human muscle cell‐based models using CRISPR technology to explore the pathophysiology of cystinosis myopathy with the potential to develop new therapies. We used a 4‐day differentiation protocol of myoblasts into myotubes to study the effect of CTNS loss in key regulators of myogenic differentiation using western blot analysis. Afterwards, we used lentiviral (LV)‐mediated CTNS WT cDNA addition in CTNS −/− cells to corroborate the CTNS‐specific effect. As a next step, we performed multiomic analysis (proteomics, transcriptomics and metabolomics) to gain in‐depth knowledge of affected mechanisms.
Results
The polyclonal, isogenic human CTNS knock‐out (KO; CTNS −/− ) myoblasts exhibited unaltered growth characteristics and accumulated cystine. Early‐stage differentiation of myoblasts into myotubes showed a mild reduction in the fusion index of CTNS −/− myotubes. Upon examination of several key regulators of myogenic differentiation, we observed significantly decreased myosin heavy chain (MyHC) and ryanodine receptor (RyR) protein levels in CTNS −/− myotubes compared to WT cells. Complementation with CTNS WT cDNA addition in CTNS −/− cells rescued the fusion index, cystine and altered protein levels to WT. In addition, proteomic analysis showed no differences at myoblast level upon the loss of CTNS, but following myotube differentiation, CTNS deletion led to an increase of five protein groups mainly involved in oxidative stress pathways, and a decrease of 18 protein groups biologically connected in myofibril assembly and muscle cell differentiation processes. Importantly, LV‐mediated CTNS addback reverted protein levels to WT levels. Moreover, metabolomics revealed a distinct clustering resulting from CTNS loss.
Conclusions
Muscle‐specific complications are often overlooked in systemic cystinosis treatment. We show that defective CTNS function impairs effective cystine mobilization from lysosomes, thereby affecting the protein levels of myogenic regulators. A deeper understanding of the molecular mechanisms underlying cystinosis myopathy holds promise for the development of targeted, personalized therapies to improve the quality of life for patients living with cystinosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Advanced Disease Modelling, Targeted Drug Discovery and Gene Therapy (ADVANTAGE), Department of Pharmacological and Pharmaceutical Sciences, Faculty of Medicine, KU Leuven, Leuven, Belgium.
- Department of Chemical Engineering, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
- Stem Cell and Developmental Biology Unit, Department of Development and Regeneration, Faculty of Medicine, KU Leuven, Leuven, Belgium.
- Laboratory for Molecular and Cellular Signaling, Department of Cellular and Molecular Medicine, Faculty of Medicine, KU Leuven, Leuven, Belgium.
- Emma Children Hospital Amsterdam UMC, Amsterdam, AZ, the Netherlands.
- Myoline Platform, Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
ORCID-Profile: Roger Mora, Rik Gijsbers
Förderung
- Research Foundation Flanders (FWO)
- Cystinosis Ireland
- Cystinosis Foundation UK
- EU ERA4Health CARDINNOV AmnioSMART
- INTERREG Euregio Meuse-Rhine
- Small Research Infrastructure KU Leuven BioAssemblyBot 400
- Ricerca Finalizzata from the Italian Ministry of Health
- KU Leuven Rondoufonds voor Duchenne Onderzoek
Zitieren
APA
Medaer, L., Mora, R., Zhou, Z., Giarratana, N., Yedigaryan, L., La Rovere, R., Levtchenko, E., Mouly, V., Verhoeyen, E., Eeltink, S., Treumann, A., Vervliet, T., Sampaolesi, M., & Gijsbers, R. (2025). An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70116
Vancouver
Medaer L, Mora R, Zhou Z, Giarratana N, Yedigaryan L, La Rovere R, et al. An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins. Journal of Cachexia, Sarcopenia and Muscle. 2025. doi:10.1002/jcsm.70116
BibTeX
@article{Medaer2025,
author = {Medaer, Louise and Mora, Roger and Zhou, Zhuoheng and Giarratana, Nefele and Yedigaryan, Laura and La Rovere, Rita and Levtchenko, Elena and Mouly, Vincent and Verhoeyen, Els and Eeltink, Sebastiaan and Treumann, Achim and Vervliet, Tim and Sampaolesi, Maurilio and Gijsbers, Rik},
title = {An Isogenic Human Myoblast Cell Model for Cystinosis Myopathy Reveals Alteration of Key Myogenic Regulatory Proteins},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2025},
doi = {10.1002/jcsm.70116}
}
EUVIMED